GlassScriptPhysician profile
Elaine Yee
NPI 1720006802
$8,467.00
in general payments reported to CMS, 2019-2025
31 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $956 · 2021: $2,542 · 2022: $1,195 · 2023: $1,144 · 2024: $746 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,379.95 | 2019-2024 | Sunlenca, Biktarvy, Veklury |
| Cipla USA INC. | $1,220.51 | 2021 | |
| Abbvie INC. | $1,047.59 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Allergan, INC. | $860.33 | 2019-2020 | |
| Viiv Healthcare Company | $539.82 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $528.34 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Astellas Pharma US INC | $459.35 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $415.32 | 2021-2025 | Xerava |
| Pfizer INC. | $187.88 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $181.25 | 2019-2025 | Nuzyra |
| Ferring Pharmaceuticals INC. | $158.59 | 2023-2025 | Rebyota |
| Janssen Biotech, INC. | $152.54 | 2019-2022 | |
| Insmed, INC. | $137.02 | 2019-2025 | Arikayce |
| Tetraphase Pharmaceuticals, INC. | $135.39 | 2019-2020 | |
| Acell, INC. | $115.85 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $113.24 | 2023 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.03 | 2023 | Lifevest |
| Melinta Therapeutics, LLC | $100.65 | 2022 | |
| Aimmune Therapeutics, INC. | $100.38 | 2024-2025 | Zenpep |
| Janssen Products, LP | $99.00 | 2021 | |
| Theratechnologies INC. | $76.73 | 2021-2023 | Egrifta, Trogarzo |
| Shionogi INC | $76.01 | 2022-2024 | Fetroja |
| Organogenesis INC. | $72.51 | 2021-2022 | |
| Kerecis Limited | $42.05 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Solventum Corporation | $41.22 | 2024 | V.A.C. Veraflo, Prevena |
| Amgen INC. | $25.67 | 2024 | Actimmune |
| Tactile Systems Technology INC | $22.28 | 2022 | |
| Bio Products Laboratory USA, INC. | $21.41 | 2022 | |
| Vyera Pharmaceuticals, LLC | $17.88 | 2019 | |
| Glaxosmithkline, LLC. | $14.78 | 2022 | |
| Biomerieux INC | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.